Apnimed Announces FDA Acceptance of New Drug Application for AD109, An Investigational Oral Pill to Treat Adults with Obstructive Sleep Apnea

Дата публикации: 14-07-2026 01:07:22

CAMBRIDGE, Mass., July 14, 2026 – Apnimed, Inc., a late stage clinical pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing...

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy	0	8.61	15-07-2026
2	Sleep Apnea Sufferers May Soon Be Able To Reach for a Pill To Deal With Their Condition	0	8.46	13-03-2026
3	Saol Therapeutics Announces the Acceptance of Resubmission of SL1009 (DCA) by the FDA with PDUFA Date of Dec. 30, 2026	0	15.84	28-07-2026
4	BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1	0	20.6	22-07-2026
5	Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks	0	17.66	06-07-2026
6	Lundbeck Receives FDA Fast Track Designation for Lu AH69593, an Investigational Orexin 2 Receptor Agonist for Narcolepsy	0	13.22	23-07-2026
7	Camurus’ NDA Resubmission for CAM2029 in Acromegaly Accepted for Review by the US FDA	0	10.06	17-07-2026
8	Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors	0	13.2	08-07-2026
9	Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility	0	13.33	07-08-2026
10	Saol Therapeutics Resubmits the New Drug Application for SL1009 (DCA) for the Treatment of Pyruvate Dehydrogenase Complex Deficiency (PDCD), an Ultra-Rare Disease	0	12.73	07-07-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 14.56. Источник: www.drugs.com.